Amendment to Certain Agreements. The Company shall not enter into or consent to any amendment, supplement or other modification of the Operative Documents except as permitted under Article 9 hereof.
Amendment to Certain Agreements. Except as expressly provided for in the Transaction Documents, no Indenture Obligor shall, nor shall it permit any of its Obligor Subsidiaries to, amend, modify or supplement, or permit or consent to any amendment, modification or supplement of, the Exit Facility, the New Other Secured Notes And Claims and the Transaction Documents, except in each case to the extent such amendment, modification or supplement could not reasonably be expected to have a Material Adverse Effect.
Amendment to Certain Agreements. Neither the Company nor any Subsidiary shall (a) enter into or consent to any amendment, supplement or other modification of this Agreement or the Security Documents except as permitted under Article IX hereof, and (b) amend, restate, supplement, modify, waive or otherwise change or consent or agree to any amendment, modification, waiver or other change to, any of the terms of the New Credit Agreement in any manner prohibited by the Intercreditor Agreement.
Amendment to Certain Agreements. (a) No Obligor shall, without the consent of the Required Lenders, on or after the Closing Date, amend, modify or change in any manner any term or condition of any Other Bilateral Debt if such amendment, modification or change would have caused the Other Bilateral Debt Restructuring Conditions not to have been satisfied as of the Closing Date if such amendment, modification or change had occurred on or prior to such date;
Amendment to Certain Agreements. (a) Sections 4.1 and 7.2 of this Agreement shall, effective as of the date of this Agreement, supersede and replace Sections 20.16 and 20.17 of the Aventis Collaboration Agreement. The foregoing sentence shall not impair the rights of the Company or constitute a waiver by the Company of any breach or default by Aventis, Sanofi US or any of their Affiliates under Sections 20.16 and 20.17 of the Aventis Collaboration Agreement. Sanofi, the Investor, Sanofi US and the Company agree that Section 19.5 of the Aventis Collaboration Agreement is hereby amended and restated in its entirety to read: “Notwithstanding anything to the contrary herein, Regeneron will have the unilateral right to terminate this Agreement in its entirety, upon written notice to Aventis, if any of the Standstill Parties (as defined in the Amended and Restated Investor Agreement, dated as of January 11, 2014 (the “Investor Agreement”), by and among Sanofi, sanofi-aventis US LLC, Aventis, sanofi-aventis Amérique du Nord and Regeneron) shall have breached Section 4.1 of the Investor Agreement. For the avoidance of doubt, Regeneron shall not have the right to terminate this Agreement as a result of a de minimis breach of Section 4.1(a) of the Investor Agreement or an inadvertent breach of Section 4.1(g) of the Investor Agreement arising from informal discussions covering general corporate or other business matters the purpose of which is not intended to effectuate or lead to any of the actions referred to in paragraphs (a) through (e) of Section 4.1 of the Investor Agreement.” (b) Sanofi, the Investor, Sanofi US and the Company agree that Section 19.5 of the Sanofi License and Collaboration Agreement is hereby amended and restated in its entirety to read: “Regeneron shall have the unilateral right to terminate this Agreement in its entirety, effective immediately upon written notice to Sanofi, if Sanofi or any of its Affiliates shall have breached their obligations under any of Sections 4, 5 or 6 of the Investor Agreement (to the extent such sections of the Investor Agreement is then in effect). Furthermore, Regeneron shall have the unilateral right to terminate this Agreement in its entirety, effective immediately upon written notice to Sanofi, if Sanofi or any of its Affiliates shall have (a) breached their obligations under Section 20.16 of the Aventis Collaboration Agreement, to the extent that such Section 20.16 remains in effect after the Effective Date, or (b) breached its obligations u...
Amendment to Certain Agreements. 70 5.25 Waiver of Stay, Extension or Usury Laws.................................... 71
Amendment to Certain Agreements. Neither the Issuer nor any Restricted Subsidiary shall (a) enter into or consent to any amendment, supplement or other modification of (i) this Indenture except as permitted under ARTICLE X hereof or (ii) the Collateral Documents except as permitted under the Intercreditor PANAVISION 12.5% SENIOR SECURED NOTES DUE 2009 INDENTURE 56 Agreement, or following the termination of the Intercreditor Agreement, ARTICLE X hereof, (b) amend, modify, waive or otherwise change, or consent or agree to any amendment, modification, waiver or other change to, any of the terms of the Existing Senior Subordinated Securities or the Mafco Line of Credit (other than any such amendment, modification, waiver or other change which (i) (x) would extend the maturity or reduce the amount of any payment of principal thereof or which would reduce the rate or extend the date for payment of interest thereon and are otherwise no less favorable to the Holders (including without limitation the subordination provisions thereof), or (y) would not have an adverse effect on the Holders), and (ii) with respect to the Mafco Line of Credit does not involve the payment of a consent fee, and (c) amend, restate, supplement, modify, waive or otherwise change or consent or agree to any amendment, modification, waiver or other change to, any of the terms of the Senior Credit Facility in any manner prohibited by the Intercreditor Agreement. Without the prior written consent of the Majority Holders, neither the Issuer nor any Restricted Subsidiary shall agree to any amendment or modification of, or supplement to the Senior Credit Facility, the effect of which is to: (i) prohibit payments in respect of the Note Obligations that are otherwise permitted under the terms of the Senior Credit Agreement, as in effect on the date hereof; (ii) increase the level of fees and interest by more than two percent (2.0%) above the rate otherwise applicable under the Senior Credit Agreement as in effect on the date hereof; or (iii) make the Stated Maturity of the Senior Credit Agreement earlier than as set forth in the Senior Credit Agreement as of the date hereof.
Amendment to Certain Agreements. As promptly as possible following the execution of this Agreement, the Company will use commercially reasonable efforts to negotiate an amendment to License Agreement, dated as of September 18, 2003, entered into by and between The Cleveland Clinic Foundation and the Company (as successor to VenPro Corporation), as amended by the Amendment to License Agreement, dated as of November 16, 2004, entered into by and between The Cleveland Clinic Foundation and the Company in form and substance reasonably acceptable to Parent.
Amendment to Certain Agreements. The Issuer shall not enter into or consent to any amendment, supplement or other modification of this Indenture or the Collateral Documents except as permitted under Article X hereof.
Amendment to Certain Agreements. 55 Section 5.12 Title to Collateral; Limitation on Liens.......................................... 55 Section 5.13 Books, Records, Access; Confidentiality........................................... 55 Section 5.14 Security Interests................................................................ 56 Section 5.15 Repurchase of Notes Upon a Change in Control...................................... 56 Section 5.16 Restrictions on Becoming an Investment Company.................................... 57 Section 5.17 Limitation on Indebtedness........................................................ 57 Section 5.18 Limitation on Distributions from Restricted Subsidiaries.......................... 59 Section 5.19 Limitation on Sales of Assets and Subsidiary Stock................................ 61 Section 5.20 Limitation on Affiliate Transactions.............................................. 62 Section 5.21 Limitation on the Sale or Issuance of Capital Stock of Restricted Subsidiaries.... 63 Section 5.22 Limitation on Guarantees by Restricted Subsidiaries............................... 63 Section 5.23 Limitation on Sale/Leaseback Transactions......................................... 64 Section 5.24 Excess Cash Flow Offer............................................................ 64 ARTICLE VI SUCCESSORS................................................................................. 65
